参考文献/References:
[1] Lee YJ,Suh Y,Kim JS,et al. Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk:the subanalysis from the TICO trial[J]. Korean Circ J,2022,52(4):324-337. [2] Kang J,Kim HS. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention:focus on unique feature of East Asian and “Asian Paradox”[J]. Korean Circ J,2018,48(7):537-551. [3] Faber DR,de Groot PG,Visseren FL. Role of adipose tissue in haemostasis,coagulation and fibrinolysis[J]. Obes Rev,2009,10(5):554-563. [4] Jeong YH. “East asian paradox”:challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome[J]. Curr Cardiol Rep,2014,16(5):485. [5] Yang M,Ye Z,Mei L,et al. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis[J]. Eur J Clin Pharmacol,2021,77(12):1815-1823.[6] Storey RF,Husted S,Harrington RA,et al. Inhibition of platelet aggregation by AZD6140,a reversible oral P2Y12 receptor antagonist,compared with clopidogrel in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2007,50(19):1852-1856. [7] Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11):1045-1057. [8] de Luca L,Zeymer U,Claeys MJ,et al. Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice:a propensity score analysis of five contemporary European registries[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(2):94-103. [9] Zocca P,Kok MM,van der Heijden LC,et al. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor:insights from CHANGE DAPT[J]. Int J Cardiol,2018,268:11-17. [10] Gragnano F,Moscarella E,Calabrò P,et al. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes:insights from the multicenter START-ANTIPLATELET registry[J]. Intern Emerg Med,2021,16(2):379-387. [11] Wiviott SD,Braunwald E,McCabe CH,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2007,357(20):2001-2015. [12] Schüpke S,Neumann FJ,Menichelli M,et al. Ticagrelor or prasugrel in patients with acute coronary syndromes[J]. N Engl J Med,2019,381(16):1524-1534. [13] Zhang J,Qiu M,Na K,et al. Impact of 6- versus 12-month dual antiplatelet therapy on clinical prognosis in patients with high bleeding risk:insights from the 4-year results of the I LOVE IT 2 study[J]. Catheter Cardiovasc Interv,2021,97(suppl 2):1025-1031. [14] Kim BK,Hong SJ,Cho YH,et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome:the TICO randomized clinical trial[J]. JAMA,2020,323(23):2407-2416. [15] Escaned J,Cao D,Baber U,et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention:TWILIGHT-HBR[J]. Eur Heart J,2021,42(45):4624-4634. [16] Costa F,van Klaveren D,James S,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT) score:a pooled analysis of individual-patient datasets from clinical trials[J]. Lancet,2017,389(10073):1025-1034. [17] Valgimigli M,Frigoli E,Heg D,et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk[J]. N Engl J Med,2021,385(18):1643-1655. [18] Kandzari DE,Kirtane AJ,Windecker S,et al. One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients[J]. Circ Cardiovasc Interv,2020,13(11):e009565. [19] Mehran R,Cao D,Angiolillo DJ,et al. 3- or 1-Month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation[J]. JACC Cardiovasc Interv,2021,14(17):1870-1883.[20] Valgimigli M,Cao D,Angiolillo DJ,et al. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI[J]. J Am Coll Cardiol,2021,78(21):2060-2072. [21] Valgimigli M,Smits PC,Frigoli E,et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk:a MASTER DAPT trial sub-analysis[J]. Eur Heart J,2022,43(33):3100-3114.?[22] Doyle BJ,Ting HH,Bell MR,et al. Major femoral bleeding complications after percutaneous coronary intervention:incidence,predictors,and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005[J]. JACC Cardiovasc Interv,2008,1(2):202-209. [23] 韩雅玲. 中国经皮冠状动脉介入治疗指南(2016)[J]. 中华心血管病杂志,2016,44(5): 382-400.[24] 中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等. 冠心病双联抗血小板治疗中国专家共识[J]. 中华心血管病杂志,2021,49(5):432-454.[25] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志,2019,47(10):766-783.[26] Bajraktari G,Rexhaj Z,Elezi S,et al. Radial access for coronary angiography carries fewer complications compared with femoral access:a meta-analysis of randomized controlled trials[J]. J Clin Med,2021,10(10):2163. [27] Ferrante G,Rao SV,Jüni P,et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease:a meta-analysis of randomized trials[J]. JACC Cardiovasc Interv,2016,9(14):1419-1434. [28] Valgimigli M,Gagnor A,Calabró P,et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management:a randomised multicentre trial[J]. Lancet,2015,385(9986):2465-2476. [29] Tarighatnia A,Farajollahi AR,Mohammadalian AH,et al. Radiation exposure levels according to vascular access sites during PCI:a prospective controlled study[J]. Herz,2019,44(4):330-335. [30] 中国医师协会心血管内科医师分会,中国医师协会心血管内科医师分会血栓防治专业委员会,中华医学会消化内镜学分会,等. 急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识[J]. 中华内科杂志,2016,55(10):813-824.[31] Robinson M,Horn J. Clinical pharmacology of proton pump inhibitors:what the practising physician needs to know[J]. Drugs,2003,63(24):2739-2754. [32] Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021,42(14):1289-1367. [33] Agewall S,Cattaneo M,Collet JP,et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy[J]. Eur Heart J,2013,34(23):1708-1713,1713a-1713b.
相似文献/References:
[1]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[2]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[3]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(7):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(7):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(7):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(7):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[8]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(7):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(7):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[10]魏倩 梁岩.高敏心肌肌钙蛋白在急性冠脉综合征患者中的临床应用进展[J].心血管病学进展,2021,(5):396.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.003]